Acromegaly and gigantism share the same underlying cause: sustained, uncontrolled excess growth hormone. What differs is simply the timing relative to skeletal maturity — whether the excess begins before or after the growth plates in long bones have fused.
This shared mechanism is why the two conditions are discussed together in endocrinology literature despite looking quite different clinically, and why the same underlying treatment approach often applies to both once diagnosed.
In children, whose growth plates remain open, excess growth hormone drives unusually rapid and excessive linear growth, producing gigantism — a condition marked by height significantly beyond typical ranges for age, alongside other systemic effects of chronic GH excess.
Because it occurs during an active growth period, gigantism is often identified relatively early through unusually rapid height gain, prompting the diagnostic workup that reveals the underlying excess.
In adults, whose growth plates have already fused, the same excess instead causes bones and soft tissue to thicken rather than lengthen, producing the progressive enlargement of hands, feet, jaw, and facial features characteristic of acromegaly, along with potential internal organ involvement.
Because these changes develop gradually, acromegaly is sometimes diagnosed years after onset, once the cumulative physical changes become clinically apparent or associated complications prompt medical evaluation.
The vast majority of documented cases trace back to a benign pituitary adenoma — a non-cancerous tumor that secretes growth hormone independent of the body's normal regulatory feedback. Left untreated, chronic excess is associated with cardiovascular strain, joint disease, and elevated diabetes risk.
This is general medical background information, not a diagnostic resource or medical advice. REVIVE LAB UAE does not sell HGH, and nothing in this article should be used to self-assess or self-treat a suspected hormone condition.